Associations between lifetime classic psychedelic use and cardiometabolic diseases

Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychede...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Otto Simonsson, Walter Osika, Robin Carhart-Harris, Peter S. Hendricks
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da2659
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1bec952e2b6e4e63b6ebf6dd00da2659
record_format	dspace
spelling	oai:doaj.org-article:1bec952e2b6e4e63b6ebf6dd00da26592021-12-02T15:33:13ZAssociations between lifetime classic psychedelic use and cardiometabolic diseases10.1038/s41598-021-93787-42045-2322https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da26592021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93787-4https://doaj.org/toc/2045-2322Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.Otto SimonssonWalter OsikaRobin Carhart-HarrisPeter S. HendricksNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Otto Simonsson Walter Osika Robin Carhart-Harris Peter S. Hendricks Associations between lifetime classic psychedelic use and cardiometabolic diseases
description	Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.
format	article
author	Otto Simonsson Walter Osika Robin Carhart-Harris Peter S. Hendricks
author_facet	Otto Simonsson Walter Osika Robin Carhart-Harris Peter S. Hendricks
author_sort	Otto Simonsson
title	Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_short	Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_full	Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_fullStr	Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_full_unstemmed	Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_sort	associations between lifetime classic psychedelic use and cardiometabolic diseases
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da2659
work_keys_str_mv	AT ottosimonsson associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases AT walterosika associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases AT robincarhartharris associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases AT petershendricks associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases
_version_	1718387068170665984

Associations between lifetime classic psychedelic use and cardiometabolic diseases

Ejemplares similares